Improved efficacy with maintained tolerability in the treatment of primaryhypertension. Comparison between the felodipine-metoprolol combination tablet and monotherapy with enalapril

In this multicentre, double-blind, parallel-group study, 120 out-patients w ith mild to moderate primary hypertension were randomised, after a 4-week s ingle-blind placebo run-in period, to a combination tablet of felodipine-me toprolol 5/50 mg (Logimax(R), Mobloc(R), Astra) once daily or enalapril 10 mg once daily. If blood pressure (BP) remained suboptimally controlled afte r 4 weeks (supine diastolic BP >90 mm Hg 24-h post dose), the dose was doub led for a further 4 weeks. After 8 weeks felodipine-metoprolol reduced supi ne BP significantly more than enalapril (19.7/12.0 mmHg and 11.1/7.2 mm Hg, respectively). The mean differences in change in BP between treatments wer e 8.6/4.8 mm Hg in favour of felodipine-metoprolol (P = 0.001/P < 0.001). A statistically significant difference to the advantage of felodipine-metopr olol was also seen in standing BP. Even though the dose was increased in a larger proportion of patients in the enalapril group (61%) than in the felo dipine-metoprolol group (40%), fewer enalapril-treated patients achieved ad equate BP control (41% vs 63% on felodipine-metoprolol, P<0.05). Both treat ments were well tolerated. Three patients treated with felodipine-metoprolo l and four with enalapril discontinued treatment due to adverse events. A s imilar number of patients reported adverse events in each treatment group. In conclusion, a combination tablet of felodipine-metoprolol 5/50-10/100 mg once daily reduced BP more effectively than enalapril 10-20 mg once daily 24 h post dose. The result was expected, but a more important observation w as that both treatments were tolerated to a similar degree. Obviously, a co nsiderable BP reduction may be well tolerated, as was the main purpose to d emonstrate in this study.